OralParenteralDosed ingredientTherapeutic flag
Haloperidol
CAS 52-86-8
Haloperidol (CAS 52-86-8) is a Phase 4 pharmaceutical compound with 48 bioactivity targets and 2,675 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
93
SOURCE
DrugCentral
Adverse signals
2,675
SOURCE
IUPHAR/BPS
PubMed IDs
60
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Haloperidol
CAS Number
52-86-8
UNII
J6292F8L3D
InChIKey
LNEPOXFFQSENCJ-UHFFFAOYSA-N
ChEMBL ID
CHEMBL54
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
HALOPERIDOL DECANOATEhaloperidol lactateHaldol
black box warningdosed ingredientoralparenteraltherapeutic flag
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL54 | Small molecule
SOURCE
EMBL-EBI ChEMBL
80 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 404.21271789099524 nM | 829 | - |
| - | IC50 | 4078.638089803922 nM | 247 | - |
| - | AC50 | 16959.248639053254 nM | 168 | - |
| - | Potency | 14189.426470588236 nM | 66 | - |
| - | GI50 | 34401.98072727273 nM | 55 | - |
| - | Kd | 16681.804422222223 nM | 9 | - |
| - | EC50 | 10002.822857142857 nM | 7 | - |
| - | MIC | 57300 nM | 6 | - |
| - | MIC | 3.125 ug.mL-1 | 2 | - |
| - | EC50 | 0.2 mg kg-1 | 1 | - |
| - | EC50 | 0.88 umol/Kg | 1 | - |
| Calmodulin Cytosolic other |
IC50 | 6.3 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 5A GPCR |
Ki | 5.648 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 1F GPCR |
Ki | 5.301 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 1E GPCR |
Ki | 5.301 | - | Homo sapiens |
| Beta-2 adrenergic receptor GPCR |
Ki | 5.301 | - | Homo sapiens |
| Mu-type opioid receptor GPCR |
Ki | 6.003 | - | Homo sapiens |
| D(1A) dopamine receptor GPCR |
Ki | 7.82 | - | Homo sapiens |
| D(2) dopamine receptor GPCR |
Ki | 9.15 | - | Homo sapiens |
| Alpha-2A adrenergic receptor GPCR |
Ki | 5.947 | - | Homo sapiens |
| Sigma non-opioid intracellular receptor 1 Membrane receptor |
EC50 | 8.92 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily H member 2 Ion channel |
IC50 | 7.5 | - | Homo sapiens |
| 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme |
Ki | 6.72 | - | Homo sapiens |
| Multidrug resistance protein 1 Transporter |
Ki | 6.7 | - | Homo sapiens |
| Sodium-dependent serotonin transporter Transporter |
Ki | 5.74 | - | Homo sapiens |
| Sodium-dependent noradrenaline transporter Transporter |
Ki | 5.74 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 1A GPCR |
Ki | 5.55 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2A GPCR |
Ki | 7 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2B GPCR |
Ki | 6.1 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2C GPCR |
Ki | 5.33 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 6 GPCR |
Ki | 5.22 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 7 GPCR |
Ki | 6.45 | - | Homo sapiens |
| Alpha-1A adrenergic receptor GPCR |
Ki | 7.9 | - | Homo sapiens |
| Alpha-2B adrenergic receptor GPCR |
Ki | 6.319 | - | Homo sapiens |
| D(3) dopamine receptor GPCR |
Ki | 8.52 | - | Homo sapiens |
| D(1B) dopamine receptor GPCR |
Ki | 7.52 | - | Homo sapiens |
| Histamine H1 receptor GPCR |
Ki | 6.36 | - | Homo sapiens |
| Histamine H2 receptor GPCR |
Ki | 5.999 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M1 GPCR |
Ki | 5.8 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M3 GPCR |
Ki | 5 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M5 GPCR |
Ki | 6.182 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 1B GPCR |
Ki | 6.569 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 1D GPCR |
Ki | 6.6 | - | Homo sapiens |
| Alpha-2C adrenergic receptor GPCR |
Ki | 6.26 | - | Homo sapiens |
| Alpha-1D adrenergic receptor GPCR |
Ki | 7.553 | - | Homo sapiens |
| Alpha-1B adrenergic receptor GPCR |
Ki | 8.097 | - | Homo sapiens |
| Potassium channel subfamily K member 2 Ion channel |
IC50 | 5.26 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily H member 1 Ion channel |
IC50 | 6.2 | - | Homo sapiens |
| Alpha-1B adrenergic receptor GPCR |
Ki | 8.305 | - | Rattus norvegicus |
| Membrane-associated progesterone receptor component 1 Membrane receptor |
Ki | 7.444 | - | Rattus norvegicus |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Neuroleptic malignant syndrome | 1425 | 4095.68 | 10029282 |
| Extrapyramidal disorder | 1264 | 3616.483 | 10015832 |
| Intentional self-injury | 760 | 1522.98 | 10022524 |
| Akathisia | 560 | 1375.96 | 10001540 |
| Dystonia | 607 | 1347.992 | 10013983 |
| Catatonia | 358 | 937.235 | 10007776 |
| Drug interaction | 1680 | 930.408 | 10013710 |
| Muscle rigidity | 452 | 924.612 | 10028330 |
| Agitation | 800 | 841.141 | 10001497 |
| Psychotic disorder | 540 | 783.3 | 10061920 |
| Parkinsonism | 375 | 754.958 | 10034010 |
| Sedation | 569 | 738.531 | 10039897 |
| Salivary hypersecretion | 345 | 714.265 | 10039424 |
| Delirium | 655 | 689.458 | 10012218 |
| Sopor | 423 | 673.428 | 10058709 |
| Electrocardiogram QT prolonged | 658 | 656.819 | 10014387 |
| Hyperprolactinaemia | 228 | 615.854 | 10020737 |
| Hallucination, auditory | 355 | 612.717 | 10019070 |
| Aggression | 506 | 608.515 | 10001488 |
| Tardive dyskinesia | 299 | 606.19 | 10043118 |
| Suicide attempt | 613 | 587.261 | 10042464 |
| Delusion | 337 | 564.094 | 10012239 |
| Arthralgia | 93 | 496.722 | 10003239 |
| Blood creatine phosphokinase increased | 482 | 487.383 | 10005470 |
| Somnolence | 988 | 483.564 | 10041349 |
| Intentional overdose | 568 | 422.883 | 10022523 |
| Pain | 238 | 411.833 | 10033371 |
| Schizophrenia | 245 | 401.897 | 10039626 |
| Fatigue | 445 | 387.828 | 10016256 |
| Weight increased | 1038 | 381.21 | 10047899 |
| Dyskinesia | 362 | 370.388 | 10013916 |
| Tachycardia | 704 | 364.089 | 10043071 |
| Rhabdomyolysis | 505 | 363.604 | 10039020 |
| Tremor | 706 | 346.512 | 10044565 |
| Restlessness | 343 | 340.097 | 10038743 |
| Psychomotor hyperactivity | 224 | 327.084 | 10037211 |
| Rash | 210 | 322.578 | 10037844 |
| Hypothermia | 238 | 320.978 | 10021113 |
| Headache | 235 | 320.248 | 10019211 |
| Joint swelling | 25 | 320.147 | 10023232 |
| Antipsychotic drug level below therapeutic | 119 | 317.398 | 10060145 |
| Coma | 479 | 316.756 | 10010071 |
| Toxicity to various agents | 1107 | 307.316 | 10070863 |
| Infusion related reaction | 13 | 286.696 | 10051792 |
| Rheumatoid arthritis | 7 | 284.425 | 10039073 |
| Torsade de pointes | 205 | 281.537 | 10044066 |
| Abnormal behaviour | 282 | 269.177 | 10061422 |
| Hypertonia | 147 | 264.654 | 10020852 |
| Overdose | 647 | 258.448 | 10033295 |
| Disinhibition | 114 | 257.662 | 10013142 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
19 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| 5-HT 2A receptor HTR2A |
Antagonist | 6.699999809265137 pKi | 8935801|9732398|12629531|15102927|18308814 |
| D 2 receptor DRD2 |
Antagonist | 7.400000095367432 pKi | 8301582|7907989|1354163|7664822|7862709 |
| D 3 receptor DRD3 |
Antagonist | 7.5 pKi | 8301582|1354163|7862709|18308814 |
| D 4 receptor DRD4 |
Antagonist | 8.699999809265137 pKi | 8102973|7862709|18308814 |
| 5-HT 1A receptor HTR1A |
Antagonist | 5.7 pKi | 9760039|9067310|8935801|9732398 |
| 5-HT 1D receptor HTR1D |
Antagonist | 6.6 pKi | 8935801 |
| 5-HT 2A receptor Htr2a |
Antagonist | 7.4 pKi | 9655845 |
| 5-HT 2B receptor HTR2B |
Antagonist | 5.8 pKi | 9459568 |
| 5-HT 7 receptor Htr7 |
Antagonist | 6.3 pKi | 8997630|7908055|8397408 |
| 5-HT 7 receptor HTR7 |
Antagonist | 6.3 pKi | 9298538 |
| 5-HT 7 receptor Htr7 |
Antagonist | 6.3 pKi | 8394987 |
| D 1 receptor DRD1 |
Antagonist | 7.599999904632568 pKi | 1826762|18308814 |
| D 2 receptor Drd2 |
Antagonist | 8.300000190734863 pKi | 1975644 |
| D 3 receptor Drd3 |
Antagonist | 7.0 pKi | 1975644 |
| D 5 receptor DRD5 |
Antagonist | 6.3 pKi | 1826762 |
| H 1 receptor HRH1 |
Antagonist | 5.7 pKi | 8935801|12629531 |
| K ir 3.2 Kcnj6 |
Antagonist | 4.1 pEC50 | 10780978 |
| K v 10.1 KCNH1 |
Channel blocker | 6.2 pIC50 | 12522086 |
| TAS2R10 TAS2R10 |
Agonist | - | 20022913 |
SOURCE
PharmGKB
60 phenotype rows
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
CYP2D6 (PA128) CYP2D6*1, CYP2D6*1xN
CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype phenotype) is not associated with differences in treatment response or scores on the various subscales of the PANSS when treated with haloperidol or risperidone in people with Schizophrenia as compared to CYP2D6 normal metabolizer.
Evidence: -; PMID 22775532
CYP2D6 (PA128) CYP2D6*3, CYP2D6*4
CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is not associated with differences in treatment response or scores on the various subscales of the PANSS when treated with haloperidol or risperidone in people with Schizophrenia as compared to CYP2D6 normal metabolizer.
Evidence: -; PMID 22775532
HTR2C (PA194) rs3813929
Allele C is associated with increased risk of Weight gain when treated with amisulpride, clozapine, haloperidol, iloperidone, olanzapine, quetiapine, risperidone and ziprasidone as compared to allele T.
Evidence: -; PMID 21121776
HTR2C (PA194) rs3813929
Allele T is not associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele C.
Evidence: -; PMID 17702092
HTR2C (PA194) rs518147
Allele G is associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine and risperidone in people with Schizophrenia as compared to allele C.
Evidence: -; PMID 21121776
HTR2C (PA194) rs6318
Allele C is not associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele G.
Evidence: -; PMID 17702092
- rs7912580
Genotype GG is associated with increased response to haloperidol in people with Schizophrenia as compared to genotype AG.
Evidence: -; PMID 24751813
DTNBP1 (PA27512) rs909706
Genotype CT is associated with increased response to haloperidol in people with Schizophrenia as compared to genotype CC.
Evidence: -; PMID 19369910
CYP2D6 (PA128) CYP2D6*1, CYP2D6*10
CYP2D6 *10 is not associated with decreased metabolism of haloperidol as compared to CYP2D6 *1.
Evidence: -; PMID 12919180
EIF2AK4 (PA134947616) rs2412459
Genotype TT is associated with increased response to haloperidol in people with Schizophrenia as compared to genotype CT.
Evidence: -; PMID 24751813
SLC6A5 (PA35911) rs2298826
Genotype AA is associated with motor side effects when treated with haloperidol in people with Schizophrenia as compared to genotypes AG + GG.
Evidence: -; PMID 20859245
CYP2D6 (PA128) CYP2D6*1, CYP2D6*5
CYP2D6 *5 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.
Evidence: -; PMID 9352580
ANKK1 (PA134872551) rs2587550
Allele G is associated with increased response to haloperidol in people with Schizophrenia as compared to allele A.
Evidence: -; PMID 22893251
CYP2D6 (PA128) CYP2D6*1, CYP2D6*10
CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.
Evidence: -; PMID 9352580
SLC6A4 (PA312) SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)
SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with increased response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).
Evidence: -; PMID 20031235
COMT (PA117) rs4680
Genotype AG is associated with increased likelihood of extrapyramidal symptoms when treated with haloperidol in men with Schizophrenia as compared to genotypes AA + GG.
Evidence: -; PMID 23963056
DRD2 (PA27478) rs1800497
Genotype AG is not associated with likelihood of Drug Toxicity when treated with haloperidol in men with Schizophrenia as compared to genotypes AA + GG.
Evidence: -; PMID 23963056
CYP2D6 (PA128) CYP2D6*1, CYP2D6*2
CYP2D6 *2/*2 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 *1/*1 + *1/*2.
Evidence: -; PMID 12960748
CYP2D6 (PA128) CYP2D6*1, CYP2D6*10
CYP2D6 *10/*10 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 *1/*1 + *1/*10.
Evidence: -; PMID 12960748
CYP2D6 (PA128) CYP2D6 poor metabolizer
CYP2D6 poor metabolizer is not associated with concentrations of haloperidol, paliperidone and zuclopenthixol in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.
Evidence: -; PMID 26514968
EPM2A (PA27832) rs1415744
Allele C is associated with increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone or trifluoperazine in people with Schizophrenia as compared to allele T.
Evidence: -; PMID 27092952
ABCB5 (PA24387) rs17143212
Genotype CT is associated with increased Drug Toxicity when treated with haloperidol in people with Psychotic Disorders as compared to genotype CC.
Evidence: -; PMID 25647612
CYP2D6 (PA128) rs3892097
Genotype CC is associated with decreased response to haloperidol in men with Alcohol-Related Disorders, Alcoholic psychosis NOS and Alcoholism as compared to genotype CT.
Evidence: -; PMID 27695358
CYP3A43 (PA427) rs680055
Genotype CG is associated with increased response to antipsychotics, aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to genotype CC.
Evidence: -; PMID 25150845
CYP2D6 (PA128) CYP2D6 haplotype
CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of haloperidol in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.
Evidence: -; PMID 25868121
CYP3A4 (PA130) CYP3A4*1, CYP3A4*22
CYP3A4 *22 is not associated with dose-adjusted trough concentrations of antipsychotics, aripiprazole, haloperidol, pimozide or risperidone in people with Psychotic Disorders as compared to CYP3A4 *1.
Evidence: -; PMID 25868121
CYP3A4 (PA130) rs2242480
Genotype CT is associated with increased concentrations of haloperidol in people with Psychotic Disorders as compared to genotype CC.
Evidence: -; PMID 23077486
- rs12970134
Allele A is not associated with increased risk of Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.
Evidence: -; PMID 22566560
CYP2D6 (PA128) CYP2D6*6
CYP2D6 *6/*6 is associated with adverse events and extrapyramidal symptoms when treated with ciprofloxacin and haloperidol.
Evidence: -; PMID 27469576
CYP3A4 (PA130) rs2242480
Genotype CT is associated with increased severity of adverse events when treated with haloperidol in people with Psychotic Disorders as compared to genotype CC.
Evidence: -; PMID 23077486
SOURCE
NLM RxNorm
12 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Haloperidol | 5093 | SU | MTHSPL |
| HALOPERIDOL | 5093 | SU | MTHSPL |
| haloperidol | 5093 | SU | MTHSPL |
| HALOPERIDOL DECANOATE | 26420 | SU | MTHSPL |
| haloperidol decanoate | 26420 | SU | MTHSPL |
| haloperidol lactate | 217483 | SU | MTHSPL |
| HALOPERIDOL LACTATE | 217483 | SU | MTHSPL |
| Haloperidol lactate | 217483 | SU | MTHSPL |
| haloperidol | 5093 | IN | RXNORM |
| haloperidol decanoate | 26420 | PIN | RXNORM |
| Haldol | 151839 | BN | RXNORM |
| haloperidol lactate | 217483 | PIN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abnormal behaviour | haloperidol | PT | C0233514 |
| Acute hepatic failure | haloperidol | LLT | C0162557 |
| Acute hepatic failure | haloperidol | PT | C0162557 |
| Agitation | haloperidol | LLT | C0085631 |
| Agitation | haloperidol | PT | C0085631 |
| Agitation | haloperidol | PT | C0085631 |
| Agranulocytosis | haloperidol | LLT | C0001824 |
| Agranulocytosis | haloperidol | PT | C0001824 |
| Akathisia | haloperidol | LLT | C0392156 |
| Akathisia | haloperidol | PT | C0392156 |
| Akinesia | haloperidol | LLT | C0085623 |
| Akinesia | haloperidol | PT | C0085623 |
| Alopecia | haloperidol | LLT | C0002170 |
| Alopecia | haloperidol | PT | C0002170 |
| Amenorrhoea | haloperidol | LLT | C0002453 |
| Amenorrhoea | haloperidol | PT | C0002453 |
| Anaemia | haloperidol | LLT | C0002871 |
| Anaemia | haloperidol | PT | C0002871 |
| Anaphylactic shock | haloperidol | LLT | C0002792 |
| Anaphylactic shock | haloperidol | PT | C0002792 |
| Angiopathy | haloperidol | LLT | C0042373 |
| Angiopathy | haloperidol | PT | C0042373 |
| Anorexia | haloperidol | LLT | C0003123 |
| Anxiety | haloperidol | LLT | C0003467 |
| Anxiety | haloperidol | PT | C0003467 |
| Argininosuccinate synthetase deficiency | haloperidol | LLT | C0175683 |
| Argininosuccinate synthetase deficiency | haloperidol | PT | C0175683 |
| Blood and lymphatic system disorders | haloperidol | - | C0851353 |
| Body temperature decreased | haloperidol | LLT | C0020672 |
| Body temperature decreased | haloperidol | PT | C0020672 |
| Body temperature increased | haloperidol | LLT | C0015967 |
| Body temperature increased | haloperidol | PT | C0015967 |
| Bradykinesia | haloperidol | LLT | C0233565 |
| Bradykinesia | haloperidol | PT | C0233565 |
| Breast discomfort | haloperidol | LLT | C0877338 |
| Breast discomfort | haloperidol | PT | C0877338 |
| Breast disorder | haloperidol | LLT | C0006145 |
| Breast disorder | haloperidol | PT | C0006145 |
| Breast engorgement | haloperidol | LLT | C0085688 |
| Breast engorgement | haloperidol | PT | C0085688 |
| Breast pain | haloperidol | LLT | C0024902 |
| Breast pain | haloperidol | PT | C0024902 |
| Bronchospasm | haloperidol | LLT | C0006266 |
| Bronchospasm | haloperidol | PT | C0006266 |
| Cardiac arrest | haloperidol | LLT | C0018790 |
| Cardiac arrest | haloperidol | PT | C0018790 |
| Cardiac disorder | haloperidol | LLT | C0018799 |
| Cardiac disorder | haloperidol | PT | C0018799 |
| Cataract | haloperidol | LLT | C0086543 |
| Cataract | haloperidol | PT | C0086543 |
| Catatonia | haloperidol | LLT | C0007398 |
| Catatonia | haloperidol | PT | C0007398 |
| Cholestasis | haloperidol | LLT | C0008370 |
| Cholestasis | haloperidol | PT | C0008370 |
| Cogwheel rigidity | haloperidol | LLT | C0151564 |
| Cogwheel rigidity | haloperidol | PT | C0151564 |
| Confusional state | haloperidol | LLT | C0009676 |
| Confusional state | haloperidol | PT | C0009676 |
| Connective tissue disorder | haloperidol | LLT | C0009782 |
| Connective tissue disorder | haloperidol | PT | C0009782 |
| Constipation | haloperidol | LLT | C0009806 |
| Constipation | haloperidol | PT | C0009806 |
| Convulsion | haloperidol | LLT | C0036572 |
| Convulsion | haloperidol | PT | C0036572 |
| Decreased appetite | haloperidol | PT | C0232462 |
| Depression | haloperidol | LLT | C0011570 |
| Depression | haloperidol | PT | C0011570 |
| Dermatitis | haloperidol | PT | C0011603 |
| Dermatitis exfoliative | haloperidol | LLT | C0011606 |
| Dermatitis exfoliative | haloperidol | PT | C0011606 |
| Diarrhoea | haloperidol | LLT | C0011991 |
| Diarrhoea | haloperidol | PT | C0011991 |
| Disturbance in sexual arousal | haloperidol | PT | C0855242 |
| Disturbance in sexual arousal | haloperidol | PT | C0855242 |
| Dizziness | haloperidol | LLT | C0012833 |
| Dizziness | haloperidol | PT | C0012833 |
| Drowsiness | haloperidol | LLT | C0013144 |
| Drug withdrawal syndrome neonatal | haloperidol | LLT | C0027609 |
| Drug withdrawal syndrome neonatal | haloperidol | PT | C0027609 |
| Dry mouth | haloperidol | LLT | C0043352 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Haloperidol used for in pharmaceutical contexts?
Haloperidol (CAS 52-86-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Haloperidol?
Haloperidol has 2,675 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Neuroleptic malignant syndrome, Extrapyramidal disorder, Intentional self-injury, Akathisia, Dystonia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Haloperidol also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Haloperidol.
What clinical phase is Haloperidol in?
Haloperidol is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Haloperidol?
Haloperidol has 93 bioactivity rows in this page query. Rendered target entries include Calmodulin, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 1E, Beta-2 adrenergic receptor.